Roxadustat is a novel and oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor which raises endogenous erythropoietin concentrations by stabilizing HIF (5), and it has been recently endorsed for the treatment of anemia in patients with non-dialysis CKD (6). This evidence concerns the gene EPO and anemia (phenotype).